Peginterferon beta-1a

聚乙二醇干扰素β-1a

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePeginterferon beta-1a
Drug Alias NamePEGylated INF-beta-1a培干扰素β-1apeginterferonum beta-1aPEGylated interferon beta-1aPEG-interferon-β-1a +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[6] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2014/07/17
Country/TerritoryCzechiaBelgiumBulgaria +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPontificia Universidad Catolica De ChileBiogen Netherlands BvBiogen Inc +[4] 
Inactive CompaniesJohns Hopkins UniversityNational Institute Of Allergy And Infectious Diseases (Niaid)Merck Sharp & Dohme LLC
Active IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Sclerosis
Inactive IndicationsMultiple Sclerosis, Relapsing-RemittingHepatitis C, ChronicHepatitis C +[4] 

Other Information

ATC CodeL03AB13
Related LinksDrugBankKEGG